Neurogene (NGNE) Tax Rate (2013 - 2014)
Neurogene posted quarterly Tax Rate of 0.0% for Q3 2014, down 15.0% year-on-year from 0.0% in Q3 2013, and up 384.2% on a QoQ basis from 0.0% in Q4 2013.
Neurogene (NGNE) has 2 years of Tax Rate data on file, last reported at 0.0% in Q3 2014.
- For the quarter ending Q3 2014, Tax Rate fell 15.0% year-over-year to 0.0%; the trailing twelve-month figure through Dec 2014 stood at 0.02% (changed N/A YoY), and the FY2014 full-year result was 0.0%, down 6.0% from the prior year.
- Tax Rate for Q3 2014 stood at 0.0%, up from 0.0% in the prior quarter.
- Across five years, Tax Rate topped out at 0.15% in Q3 2013 and bottomed at 0.0% in Q4 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Tax Rate (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 57.14 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 5.61 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 17.68 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -6.79 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 12.51 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 7.07 |
| 10 | Neurogene | 632.14 Mn | 632.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | 0.00 |
| Sep 30, 2014 | 0.00 |
| Dec 31, 2013 | 0.00 |
| Dec 31, 2013 | 0.00 |
| Sep 30, 2013 | 0.15 |
| Sep 30, 2013 | 0.15 |